论文部分内容阅读
目的 观察尼莫地平对高血压脑出血患者血浆神经元特异性烯醇化酶(NSE)及预后的影响。方法 将85例高血压脑出血患者随机分为对照组和尼莫地平治疗组,动态观察患者的血浆NSE水平、血肿体积、神经功能缺损程度和总的生活能力评分。结果 两组患者的血浆NSE水平在各个时间点上无明显差异,尼莫地平治疗组与对照组的临床神经功能缺损程度及生活能力评分在病程第14 d时无显著性差异,在第30、90 d时治疗组的神经功能恢复优于对照组。结论 脑出血急性期静脉应用尼莫地平有可能改善患者的预后。血浆NSE不宜做为临床评价脑出血药物疗效的指标。
Objective To observe the effect of nimodipine on plasma neuron specific enolase (NSE) and its prognosis in patients with hypertensive cerebral hemorrhage. Methods Eighty-five patients with hypertensive intracerebral hemorrhage were randomly divided into control group and nimodipine treatment group. Plasma NSE level, volume of hematoma, degree of neurological deficit and total life span were measured. Results There was no significant difference in plasma NSE levels between the two groups at all time points. There was no significant difference in clinical neurological deficit score and viability score between the nimodipine treatment group and the control group on the 14th day. At 90 days, the recovery of neurological function of the treatment group was better than that of the control group. Conclusion Intravenous nimodipine may improve the prognosis of patients with intracerebral hemorrhage. Plasma NSE should not be used as a clinical evaluation of drug efficacy of cerebral hemorrhage indicators.